US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

US IPOs and Secondary Offerings

Attovia Therapeutics (ATTO): ATTOBODY Platform Draws Interest with Sector Dedicated Investors

Attovia Therapeutics (ATTO): Phase 1 Immune Therapy Biotech Sets Terms for IPO

IPOs and Secondary Offerings

Equity Capital Markets

Attovia Therapeutics / Equity Capital Markets

<ul>
<li>Strong debut: Attovia upsized its IPO and priced above the initial range, reflecting robust institutional demand and multiple-times oversubscribed order books.</li>
<li>Orderly trading: Shares opened strongly, traded within a relatively tight range, and closed near session highs, signaling balanced aftermarket demand.</li>
<li>Clinical execution ahead: Future performance will likely depend on pipeline milestones, with investors watching whether recent first-day biotech gains are monetized.</li>
</ul>


Strong debut: Attovia upsized its IPO and priced above the initial range, reflecting robust institutional demand and multiple-times oversubscribed order books.
Orderly trading: Shares opened strongly, traded within a relatively tight range, and closed near session highs, signaling balanced aftermarket demand.
Clinical execution ahead: Future performance will likely depend on pipeline milestones, with investors watching whether recent first-day biotech gains are monetized.


Attovia Therapeutics (ATTO): Healthy Debut as Strong Demand Carries Shares Higher